Pete Salzmann leaves Lilly to head up Immunovant

6 June 2019

After 20 years in various leadership roles with US pharma major Eli Lilly (NYSE: LLY), Pete Salzmann has left to take the top job - chief executive - at a company specializing in autoimmune diseases.

Immunovant, a member of Switzerland's Roivant family of companies, anticipates initiating a Phase IIa clinical trial of IMVT-1401 for the treatment of myasthenia gravis (MG), later this quarter.

This makes it a good time for Dr Salzmann to join, bringing with him experience in bringing a number of highly-successful drugs to market, including in immunology.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK